BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220421
DTEND;VALUE=DATE:20220701
DTSTAMP:20260516T022138
CREATED:20220425T094247Z
LAST-MODIFIED:20220519T120013Z
UID:33903-1650499200-1656633599@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:This year CPhI & P-MEC China returns as a SMART event\, combining 2 months of online event with a 3-day in-person event to help you connect for an extended period. \n \n“Virtual Expo Connect”\, to be held from 21st April – 30th June 2022\, is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. \nPowered by PharmaSources.com\, Virtual Expo Connect builds the online platform adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nTo know more visit: https://www.pharmasources.com/vec2022
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect-2/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:Yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220530
DTEND;VALUE=DATE:20220602
DTSTAMP:20260516T022138
CREATED:20220303T094518Z
LAST-MODIFIED:20220303T094518Z
UID:33420-1653868800-1654127999@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Analytical Development Europe
DESCRIPTION:Uncover the Robust Analytical Methods to Guarantee Safe\, High Quality\, Consistent & Efficacious Gene Therapy Products \nIn the context of unprecedented gene therapy investment and clinical progress\, with mounting regulatory scrutiny\, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency\, quality\, and safety of gene therapy products. \nWhether you’re looking for specific characterisation\, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past\, this focused\, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors\, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand. \nJoin 150+ analytical pioneers to discover the realities of working with tools like dPCR\, AUC and HPLC\, as well as how and where these tools can be most effective in process development\, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \nTo know more visit: https://ter.li/04rwmv
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-analytical-development-europe/
LOCATION:Victoria Park Plaza Hotel\, 239 Vauxhall Bridge Road\, Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220607
DTEND;VALUE=DATE:20220610
DTSTAMP:20260516T022138
CREATED:20220207T092209Z
LAST-MODIFIED:20220207T092209Z
UID:33157-1654560000-1654819199@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy Patient Engagement Summit
DESCRIPTION:Integrate the Patient Voice to Develop Safer & More Effective Gene Therapies That Are Meaningful to Patients \n \nAs investment in gene therapies continues to grow rapidly\, more effectively engaging patients throughout development has become a priority for any company serious about building safer and more meaningful gene therapy programs. \nIn this context\, the 2nd Annual Gene Therapy Patient Engagement Summit will unite patient advocacy and engagement leaders from gene therapy and gene editing drug developers\, patient groups and patients themselves to address the specific challenges of genetic therapy patient engagement\, generating actionable insights through detailed case studies and open\, honest discussions. \nJoin us to hear directly from companies and institutions including Spark Therapeutics\, Ultragenyx\, FDA\, Global Genes\, and CRISPR Therapeutics on key topics including managing expectations across gene therapy development\, navigating patient input on one-time transformative treatments with novel clinical trial designs combined with extensive follow-ups\, and developing educational materials on gene therapy to raise awareness in collaboration with patient advocacy organizations. Leverage their knowledge and experiences to ultimately ensure effective creation and implementation of patient-centric gene therapy programs. \nTo know more visit: https://ter.li/c9d6sy
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-patient-engagement-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220613
DTEND;VALUE=DATE:20220615
DTSTAMP:20260516T022138
CREATED:20220303T102140Z
LAST-MODIFIED:20220303T102140Z
UID:33430-1655078400-1655251199@www.pharmajournalist.com
SUMMARY:Pre Filled Syringes West Coast
DESCRIPTION:SMi’s 6th Annual Conference\nPre-Filled Syringes West Coast\nJune 13 – 14\, 2022 | San Diego\, CA\, USA \nSESSING DEVICE DEVELOPMENT AND REGULATION FOR ADVANCED INNOVATION \nSMi is delighted to announce the 6th annual Pre-Filled Syringes West Coast conference\, to be held in San Diego. As part of SMi’s leading series of drug delivery device conferences\, the 2022 event will provide insights into the rapidly accelerating market of combination product development with industry\, device developer and regulatory perspectives. \n \nThe last year has seen major advances in device design and development with patient usability\, ease of use and safety remaining at the forefront. This upcoming conference will assess the industry movement towards enabling self-administration through advanced device design\, innovations in connectivity to aid the user\, and the increasing importance of biologics and novel drug product considerations for device development. Furthermore\, regulatory bodies and leaders from big pharma will give an international update on the fast-evolving industry landscape. As one of our most sought-after events\, this conference is not to be missed. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nBenefits of attending: \n\nDiscover the latest advances in innovative device design for user-centric drug delivery\nAssess evolving approaches to platforms for advanced combination product portfolios\nUncover the key considerations to ensure optimal lifecycle management for drug delivery devices\nExplore how the industry is evolving with global developments including case studies of sustainable practices for drug delivery devices and the industry’s role in mass vaccination campaigns\nEngage in interactive sessions reviewing the landscape of on-body injectors for large volume delivery and the role of connectivity for wearable devices\n\nChAiRs foR 2022: \nTina Rees\, Associate Director\, Human Factors\, Regeneron Pharmaceuticals \nNatalie Abts\, Head of Human Factors Engineering\, Genentech \nFeatured 2022 speakers include:  \n\nSriman Banerjee\, Head of Packaging Development & Commercial Device Engineering\, Takeda\nAmin Sedighiamiri\, Associate Director\, Device Development\, AstraZeneca\nJames Wabby\, Executive Director\, Head of Regulatory Strategy\, Emerging Technologies and Combination Products\, Abbvie\nKhaudeja Bano\, Executive Medical Director\, Combination Product Safety Head\, Amgen\nRachel poker\, Associate Director\, Human Factors\, AstraZeneca\nKristina Li\, Sr. Engineer II\, Technical Development\, Biogen\nsujani Nannapaneni\, Human Factors Principal Research Engineer\, Combination Product Development\, Abbvie\n\nWho should attend? \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers\n\nPrevious attendees include: \nAbbott Laboratories; AbbVie; Advanced Molding Technologies; Aegerion Pharmaceuticals; Ajinomoto Althea\, Inc.; Allergan; Allergen Inc; Almac Group; Amgen; Antares Pharma; Aptar Pharma; AstraZeneca; Baxter Healthcare; BCM Group LLC; BioMarin; Boehringer Ingelheim; Connecticut Spring & Stamping; Credence MedSystems\, Inc.; Execution Metrics\, Inc; Ferring Pharmaceuticals; Fresenius-Kabi; Genentech; Genentech\, Inc.; Gilead Sciences; Glenmark Pharmaceuticals; Harro Hofliger Verpackungsmaschinen GmbH; Inovio Pharmaceuticals; iO Lifesciences; Ionis Pharmaceuticals; Ionis Pharmaceuticals\, Inc.; Matchstick; MedImmune; MedImmune LLC; Medizap; Medtronic; Merck & Co.; Mitsubishi Gas Chemical Company\, Inc; Nemera; Nipro PharmaPackaging; NOVO Engineering\, Inc.; Novo Nordisk; Novo Nordisk A/S; One World DMG; Owen Mumford; Pfenex; Pfenex Inc; Pfizer CentreOne; RAUMEDIC INC; Regeneron; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals\, Inc.; Shire; Smithers Rapra; Steri-Tek; Stevanato Group S.p.A; Subcuject ApS; Suttons Creek Inc; Terumo Corporation; Terumo Medical Corporation; Terumo Pharmaceutical Solutions; UserWise\, Inc.; W. L. Gore & Associates\, Inc.; West Pharmaceutical Services; West Pharmaceutical Services\,; West Pharmaceuticals Services Inc; Worrell; Xeris Pharmaceuticals; ZebraSCI; zebrasci inc; ZEON CORPORATION; Zeon Specialty Materials ; Zeon Specialty Materials Inc \nFind out more here: http://www.prefilled-syringes-westcoast.com/ \nSMi Group offer direct access to key decision makers through tailored sponsorship\, exhibitor and delegate packages. For details contact Daniele Moreschi on +44 7498539226  \nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: rjones@smi-online.co.uk\nFollow us: @SMiPharm #SMiPFSUSA
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-west-coast-2022/
LOCATION:San Diego\, CA\, USA
ORGANIZER;CN="SMi Events":MAILTO:rjones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220614
DTEND;VALUE=DATE:20220617
DTSTAMP:20260516T022138
CREATED:20220202T094402Z
LAST-MODIFIED:20220202T094440Z
UID:33099-1655164800-1655423999@www.pharmajournalist.com
SUMMARY:2nd HER2-Targeted Therapies Summit
DESCRIPTION:Outcomes for HER2-expressing breast cancer are patients constantly improving; advancements in diagnostics\, trial design and innovative drug design are at an all-time high; complementing the newly accessible HER2 ‘low’ space and wider range of tumor indications; the last year has given us more progress in HER2-targeted therapies than ever before. \nAs such\, the HER2-Targeted Therapies Summit returns for its second year as the only industry-dedicated forum for large pharma\, biotech and academia to unite under one roof to discuss these developments\, gain competitive insights and ultimately turbocharge practice-changing anti-HER2 drugs to patients. \nAs the clinical and commercial opportunity of HER2-targeted therapies becomes apparent\, join us to connect with over 80+ HER2 experts and expand the clinical utility of your pipeline by exploring HER2 as a multi-tumor target. \nView the full agenda now: https://ter.li/kxq80g
URL:https://www.pharmajournalist.com/event/2nd-her2-targeted-therapies-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220614
DTEND;VALUE=DATE:20220617
DTSTAMP:20260516T022138
CREATED:20220207T102442Z
LAST-MODIFIED:20220207T102621Z
UID:33181-1655164800-1655423999@www.pharmajournalist.com
SUMMARY:2nd Tumor Myeloid-Directed Therapies Summit
DESCRIPTION:Returning in 2022\, the 2nd Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment. \nThis is your ultimate forum to identify\, validate\, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function. \nDesigned for experts working directly on myeloid-directed therapies\, and those in adjacent immuno-oncology fields\, from cell therapy to checkpoint and engager development. \nIf you’re scratching your head in attempt to enhance efficacy in solid tumors and overcome barriers in the microenvironment\, this is your 500-foot view of the intricate pathways\, interactions\, and novel target development in the tumor microenvironment \nDeep-dive into myeloid biology\, guided by 27+ industry Gurus from the likes of Pionyr Therapeutics\, Gilead Sciences\, Merck\, Verseau Therapeutics\, Carisma Therapeutics\, Pfizer and many more \nWith targets such as TREM1 and TREM2 making waves in the clinic\, analysis of CD47 candidates back-translating to next-generation therapies\, and novel dendritic cell candidates such as FTL3 in development\, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment. \nTo know more visit: https://ter.li/2067lj
URL:https://www.pharmajournalist.com/event/2nd-tumor-myeloid-directed-therapies-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220620
DTEND;VALUE=DATE:20220622
DTSTAMP:20260516T022138
CREATED:20220307T120117Z
LAST-MODIFIED:20220307T120117Z
UID:33518-1655683200-1655855999@www.pharmajournalist.com
SUMMARY:2nd Inner Ear Disorders Therapeutics Summit
DESCRIPTION:Biotech companies are paving the way to displace the cochlear implant and cater for the huge unmet need in hearing and balance disorders. The field is booming with excitement\, with pharma companies increasing investment into these pipelines in the race to successfully reverse hearing damage. \n \nReturning as an in-person event to Boston\, the 2nd Inner Ear Disorders Therapeutics Summit will unite drug developers focusing on preventative and regenerative approaches targeting the inner ear. \nDebate the clinical applicability of different modalities\, including small molecule\, stem cell and gene therapy; accurately monitor hearing loss progress\, successfully identify new targets\, optimize preclinical models\, discuss combination strategies for drugs and devices and hear the latest clinical updates and novel translatable research of the inner ear. \nJoin over 100 drug developers from the likes of Otonomy\, Sound Pharmaceuticals\, Frequency Therapeutics\, Astellas\, Sensorion\, Decibel Therapeutics and more at this 4-day disease-agnostic\, modality-agnostic event designed specifically for industry-based experts in inner ear disorders to successfully translate their therapeutics into the clinic. \nTo know more visit: https://ter.li/1wvymk
URL:https://www.pharmajournalist.com/event/2nd-inner-ear-disorders-therapeutics-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220621
DTEND;VALUE=DATE:20220624
DTSTAMP:20260516T022138
CREATED:20211018T092448Z
LAST-MODIFIED:20211203T090456Z
UID:31841-1655769600-1656028799@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China 2022
DESCRIPTION:CPhI & P-MEC China is Asia’s leading pharmaceutical show for trading\, knowledge sharing and networking. It spans all industry sectors along the pharmaceutical supply chain and is your one-stop platform to grow business in the 2nd largest pharma market in the world. CPhI & P-MEC China 2022\, with the co-located shows FDF\, bioLIVE\, Pharma Excipients\, NEX and LABWORLD China\, etc. is expected to draw near 3\,000 exhibitors and hundreds and thousands of professionals from the pharmaceutical industry. \nTo know more visit: https://bit.ly/3n5sp8w
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-2022/
LOCATION:SNIEC\, Shanghai\, China
ORGANIZER;CN="Informa Markets":MAILTO:Candice.lau@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220621
DTEND;VALUE=DATE:20220624
DTSTAMP:20260516T022138
CREATED:20220228T114841Z
LAST-MODIFIED:20220228T114841Z
UID:33407-1655769600-1656028799@www.pharmajournalist.com
SUMMARY:7th Microbiome Movement - Drug Development Summit
DESCRIPTION:The 7th Microbiome Movement – Drug Development Summit returns to Boston at a pivotal time. As the microbiome therapeutic space matures\, with more indications being pursued and more companies conducting trials\, the focus of this event – now in its 7th year – is evolving to showcase these new studies. With this progress however comes new challenges\, and we’re excited to once again be uniting over 300 microbiome pioneers to work towards overcoming these challenges and moving the whole industry closer to commercial approval. \nContinuing to unite the most forward-thinking researchers from the biopharmaceutical industry\, our unrivaled program will uncover microbiome functionality and mechanisms\, decipher translation issues and advance clinical development\, overcome the key GMP manufacturing and scale-up challenges\, whilst also discovering and applying microbiome biomarkers for improved clinical outcomes. \nThis event is the most comprehensive forum for microbiome drug developers and the perfect opportunity for the industry to take a collaborative approach to close the clinical gap\, discover the next generation of microbiome-based therapeutics\, and establish new partnerships to accelerate your research. \nTo know more visit: https://bit.ly/3hss4dD
URL:https://www.pharmajournalist.com/event/7th-microbiome-movement-drug-development-summit/
LOCATION:Revere Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220621
DTEND;VALUE=DATE:20220624
DTSTAMP:20260516T022138
CREATED:20220412T093427Z
LAST-MODIFIED:20220412T093427Z
UID:33768-1655769600-1656028799@www.pharmajournalist.com
SUMMARY:Non-Viral RNA Delivery Systems Summit
DESCRIPTION:Built with biopharmaceutical industry insights\, this in-person conference will delve into the latest advancements of non-viral RNA delivery systems such as LNPs\, exosomes and polymers to set the scene for the translation of targeted\, safe and durable delivery systems for RNA therapeutics and vaccines with improved formulation\, distribution and tissue-specificity. \nDon’t miss 20+ pioneering speakers from large pharma\, innovative biotech\, and KOLs of academia who are shaping the landscape of advanced and emerging non-viral RNA delivery systems for the RNA biopharma community worldwide.  \nJoin this meeting to hear cutting-edge science and latest data on: \n\nExpand Therapeutic Applications with Emerging Non-Viral RNA Delivery Systems\nDiscover Novel LNP & Alternative Technologies to Increase Specificity & Efficacy\nLearn About the Latest Improvements of Non-Viral Delivery Systems for the Delivery of a Broad Range of RNA Payloads\nIncrease Tissue Specific & Extrahepatic Delivery through Optimizing Formulation & Design\nDelve into the emerging Engineering\, Formulation & Packaging Methods to Improve Non- Viral RNA Delivery & Stability\n\nJoin 80+ VPs\, Heads and Directors of RNA delivery\, Formulation and Process development for a deep dive into delivery challenges and strategies of non-viral systems to fully unleash the therapeutic opportunities offered by different RNA therapeutics and vaccines. \nTo know more visit: https://ter.li/ai0qwx
URL:https://www.pharmajournalist.com/event/non-viral-rna-delivery-systems-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220627
DTEND;VALUE=DATE:20220630
DTSTAMP:20260516T022138
CREATED:20220407T094504Z
LAST-MODIFIED:20220407T094504Z
UID:33743-1656288000-1656547199@www.pharmajournalist.com
SUMMARY:3rd TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:Are you using TCRs to target solid tumors yet? \nWith Immunocore having achieved commercialization for the first TCR therapy and Adaptimmune hot on their tail\, 2022 is fast becoming the year for TCRs. \nJoin the TCR-based Therapies for Solid Tumors Summit (June 27-29) to gain knowledge to accelerate the clinical development and improve the safety of these game-changing cell therapies. \nFeaturing 24+ expert speakers\, over 80% of whom are new for 2022\, this summit will address the toughest challenges in TCR development\, such as improving TCR discovery and efficacy\, combating the tumor microenvironment\, optimizing target selection and advancing manufacturing\, preclinical and clinical processes. \nJoin leaders in the field\, including Adaptimmune\, Iovance and TScan as they examine methods to prevent cross reactivity\, increase cell fitness and infiltration\, improve therapy safety and ultimately overcome the hurdles holding back these game-changing treatments from patients in need. \nFind out more in the Event Guide: https://ter.li/sa0pnw
URL:https://www.pharmajournalist.com/event/3rd-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220628
DTEND;VALUE=DATE:20220701
DTSTAMP:20260516T022138
CREATED:20220427T101322Z
LAST-MODIFIED:20220427T101322Z
UID:33919-1656374400-1656633599@www.pharmajournalist.com
SUMMARY:11th Annual HPAPI Summit
DESCRIPTION:Undoubtedly\, the past two years have changed the pharma industry forever; new modalities are dominating pharma pipelines\, drugs are increasing in potency\, and the restrictions around product quality are tighter than ever before. \nIt is integral that the HPAPI community comes together to apply expertise in ensuring operator safety\, alongside product quality\, to the future of hazardous drug production and fully understand this new landscape\, and regulatory environment. Built in collaboration with industry experts\, the HPAPI Summit provides end-to end coverage tackling; development\, commercial manufacturing & tech transfer\, occupational toxicology\, industrial hygiene & EHS\, across small molecules\, large molecules\, drug conjugates & ATMP\, for a holistic approach to bullet-proofing your hazardous drug production. \nWith sessions championed from the likes of Merck\, Bayer\, AstraZeneca\, Takeda and more\, don’t miss this opportunity to reconnect\, reassess and re-enforce your risk management for your potent pipeline and production at the longest standing and largest global summit for highly potent API’s & hazardous drugs. \nSave up to $700 on your event pass when you book before Friday\, May 20. \nGroup discounts of up to 20% are also available when you bring your team! \nTo know more visit: https://ter.li/3csco9
URL:https://www.pharmajournalist.com/event/11th-annual-hpapi-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR